Project Grant HT94252311021
Award Date
9/30/23
Completion Date
9/29/25
Dollars Obligated
$539K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The University of Texas MD Anderson Cancer Center received a $648,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop CAR T-cell therapy targeting CD94 in T/NK cell malignancies. The award period runs from September 1, 2023 to August 31, 2025. MD Anderson is a comprehensive cancer treatment and research center that has extensive experience conducting federally funded biomedical research, including...
The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...
The University of Texas MD Anderson Cancer Center received a $647,990 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This three-year grant, effective June 1, 2024, supports research to investigate cell plasticity and epigenetic reprogramming mechanisms underlying the transition of well-differentiated to de-differentiated liposarcoma. The funding will enable basic research, translational studies, and potentially future...
The University of Texas MD Anderson Cancer Center received a Project Grant award of $412,768 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) on September 19, 2023. This award will fund the development of an "ATTACHER" microfluidic device to streamline and improve the sensitivity and specificity of isolating antigen-specific T cells from cancer patient samples. The goal is to enable rapid, unbiased identification of T cells with anti-tumor...
This $762,992 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center to map and predict therapy resistance in small cell lung cancer (SCLC) using liquid biopsies. The 3-year award, effective July 1, 2024, will enable MD Anderson to conduct personalized analyses to better understand how SCLC tumors evolve and become resistant to treatment. This work aims to...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,619,668 project grant to The University of Texas MD Anderson Cancer Center to inhibit brain metastases of HER2/neu-positive breast cancers using extracellular vesicles from renovated dendritic cells. The award began on May 1, 2024 and is scheduled for completion on April 30, 2027. The project aims to develop innovative treatments to improve outcomes for military service members and the...
The University of Texas MD Anderson Cancer Center received a $1,619,997 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on targeting ferroptosis and mitochondrial pathways in acute myeloid leukemia. The 3-year award, which commenced on September 1, 2023, will support preclinical studies, clinical trials, and other research activities at the cancer center's facilities in Houston, Texas. As a component...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $613,125 to The University of Texas M.D. Anderson Cancer Center to develop EGFRXHER3 bispecific CAR-T cells for targeting EGFR tyrosine kinase inhibitor drug-tolerant persister cells. The research aims to create innovative immunotherapies for cancer treatment, with a performance period from February 1, 2025 to January 31, 2028. As a prominent academic medical...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $718,858 to The University of Texas MD Anderson Cancer Center to support research on "DISCOVERY OF NONCANONICAL ANTIGENS IN TRIPLE-NEGATIVE BREAST CANCER FOR DEVELOPMENT OF NOVEL T CELL THERAPIES." The 3-year grant, awarded on February 15, 2025, will fund investigations into new cancer antigens and the development of innovative T...